Hepatic steatosis: what the MASH trial evidence supports — setting out what I have, and where I think it stops being reliable.
Trying to work out what would count as evidence on hepatic steatosis, before collecting any. This is the part I usually skip and it is the part that makes the rest useful.
If two explanations predict the same observation, observing it does not help. So: what observation would separate them?
Confirming the opening post from a second method, which matters more than confirming it from a second person.
Whatever the answer on hepatic steatosis turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, invite the correction.
A condition being an exclusion criterion in a trial does not mean the treatment is contraindicated. It frequently means the trialists wanted a cleaner population.
Hepatic steatosis and MASH: a phase 2 trial in semaglutide for steatohepatitis showed resolution was more frequent on treatment. Histological resolution is a surrogate for long-term clinical outcomes like cirrhosis.
Not the whole picture, but the part of it I can speak to.
Asking about a population rather than about yourself is a legitimate framing and generally gets a better answer, because the general case is answerable.
That matches what I was told, which is not the same as knowing it.
Worth separating two things that post #3 runs together.
I have been on both sides of the hepatic steatosis argument in this category within eighteen months, which should tell you how strong the evidence for either side is.
This follows post #7 rather than contradicting it.
One caution on hepatic steatosis: everything above assumes the underlying documentation is what it claims to be. That assumption is doing real work and is rarely stated.
Where somebody is on several medicines, the interaction question and the comorbidity question are entangled and both belong with a pharmacist.
Obstructive sleep apnoea: SURMOUNT-OSA used an objective endpoint, the apnoea-hypopnoea index. Reduction was substantial. Whether the benefit is weight loss or a direct drug effect is not resolved by the trial.
Building on post #8 rather than restating it.
Reporting rather than recommending, on hepatic steatosis. What happened is above. Whether it should have is a different question and not one I am qualified to answer.
Checked the hepatic steatosis claim against the primary source this morning. It survives, with a narrower scope than the version quoted here. Posting the narrower scope.
Type 2 diabetes: the population with the largest evidence base for these compounds. The SURPASS and SUSTAIN programmes established glycaemic benefit. The renal and cardiovascular benefit evidence is separate from the glycaemic benefit evidence.
I checked the source rather than the summary, and they differ.
On hepatic steatosis I would separate what is worth knowing from what is worth acting on. The first list is long and the second is short, and conflating them is how threads get heated.
Post #14 describes the usual case. This is about the unusual one.
Post-authorisation safety studies are the place where under-studied populations eventually appear, and they are public.
The step people skip is the one I have spelled out.
Registry and observational data covering excluded populations is accumulating and is weaker evidence than a trial and better than nothing.
The conclusion is tentative; the arithmetic underneath it is not.
Post #19 is the version of this I will quote in future. One addition.
Where two conditions pull in opposite directions, that is a clinical judgement rather than a lookup, and it is the kind of question a forum answers worst.
That is a description of practice, not a recommendation of it.
The number people quote for hepatic steatosis is a central estimate presented without its interval, and the interval is wide enough that the estimate is nearly uninformative on its own.
Confirming post #24 from a second method, which matters more than confirming it from a second person.
Obstructive sleep apnoea: SURMOUNT-OSA used an objective endpoint, the apnoea-hypopnoea index. Reduction was substantial. Whether the benefit is weight loss or a direct drug effect is not resolved by the trial.
Not disagreeing with anyone above, just adding the bit I keep having to look up.
Adding a small correction to the hepatic steatosis summary above rather than a disagreement with it. The substance holds; one of the figures is out by a factor that matters.
A condition that affects nutrition or absorption changes the calculus around a treatment that reduces intake, and that interaction is mostly unstudied.
Not the answer, but possibly the question that gets there.
Practical experience of hepatic steatosis, offered as one case with the conditions stated, not as a general finding. Conditions first, because they are what make it interpretable.